|
Canada-0-Embossing 公司名錄
|
公司新聞:
- Rebastinib | Deciphera
An open-label, multicenter, phase 1b 2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer
- A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in . . .
This is an open-label Phase 1b 2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors
- Open-label, multicenter, phase 1b 2 study of rebastinib in combination . . .
This is a 2-part open-label, multicenter Phase 1b 2 study of rebastinib in combination with paclitaxel Here we provide updated results (ASCO 2020) from the fully enrolled endometrial cancer (EC) cohort of the study
- Deciphera Pharmaceuticals Presents Data from Rebastinib and . . . - BioSpace
The Phase 1b 2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor activity and pharmacokinetics of multiple doses of rebastinib in patients with advanced or metastatic solid tumors
- Deciphera Pharmaceuticals Initiates a Phase 1b 2 Clinical Trial of . . .
Rebastinib is an investigational, orally administered, potent and selective inhibitor of the TIE2 kinase, the receptor for angiopoietins, an important family of vascular growth factors in the tumor microenvironment that also activate pro-tumoral TIE2 expressing macrophages
- Phase 1b 2 study of rebastinib (DCC-2036) in combination . . . - Deciphera
An open-label, multicenter, phase 1b 2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer
- One Mission, Inspired by Patients: Defeat Cancer. TM - Deciphera
The updated safety and efficacy of rebastinib at 50 mg BID in combination with paclitaxel shows encouraging results in heavily pretreated patients with PROC, with an acceptable safety profile, supporting further development
- A Phase 1b 2 Study of Rebastinib (DCC-2036) in Combination With . . .
This is an open-label Phase 1b 2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors
- DCC-2036-01-004 - cdn. clinicaltrials. gov
An Open-Label, Multicenter, Phase 1b 2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors
- An Open-Label, Multicenter, Phase 1b 2 Study of Rebastinib (DCC-2036 . . .
This Phase 1b 2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor
|
|